Determination of serum imatinib and its' metabolite in patients chronic myeloid leukemia

Onmaz, Duygu Eryavuz; Abuşoğlu, Sedat; Ünlü, Ali; Baştürk, Abdulkadir; Dağlı, Mehmet; Bağcı, Metin; Tok, Ö.; Abuşoğlu, Gülsüm

doi:10.1016/j.cca.2019.07.025

Cited by 7 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found the deviation was less than 12%, which suggests that the whole blood samples retained similar stability under the above conditions. We established a methodology for imatinib and its metabolite and compared this with the methods used in other laboratories; we further increased the linearity range 32 . All the above results suggest that the mass spectrometry methodology established for imatinib and its metabolite in this study is stable and meets the EMA guidelines, which were successfully applied to imatinib TDM in clinical practice.…”

Section: Discussionmentioning

confidence: 65%

Therapeutic Drug Monitoring of Imatinib and N‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study

Huang

Liu

Chen

et al. 2023

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Imatinib is an oral tyrosine kinase inhibitor and first‐line therapy for chronic myeloid leukemia (CML) patients. There is a positive correlation between serum imatinib concentrations and treatment response. However, the specific relationship between plasma concentration of imatinib and its influencing factors remains unclear. This study collected the basic information of 102 patients using imatinib as the first‐line CML treatment drug. Further, we analyzed the individual differences in imatinib concentration and explored its influencing factors. Through the intra‐day and inter‐day precision studies, we found the precision for imatinib assay methodology was both within ± 13%, and the recovery rate was above 85%. The blood concentration of imatinib had a noticeable individual difference, and the recommended treatment concentration is 860–1500 ng/mL, with only 41.40% of patients achieving this concentration. Meanwhile, there was a negative correlation between age and imatinib trough concentration (Ctrough), the same as that between age and N–desmethyl imatinib. Besides, compared with the teenage group, the serum imatinib Ctrough aged 17∼47 years and 48∼68 years were significantly reduced. Further analysis shows that imatinib Ctrough values reached therapeutic concentrations (59%) increased dramatically in CML patients from 17 to 47 years. Moreover, the dose groups of 400 mg/d resulted in therapeutic imatinib concentrations in 68% of CML patients, which was the best. The established method was validated with acceptable accuracy, precision, linearity, and stability as required, which was successfully applied to the TDM of imatinib. Age, dose, and metabolites can influence the imatinib concentration and its therapeutic effect in CML patients.This article is protected by copyright. All rights reserved

show abstract

Section: Discussionmentioning

confidence: 65%

Therapeutic Drug Monitoring of Imatinib and N‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study

Huang

Liu

Chen

et al. 2023

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…However, on the one hand, 1 in 2-4 patients with GISTs still exhibits a low response to IM because of intolerance or adverse effects (Bednarski et al, 2014). On the other hand, nearly 10-15% of early chronic stage patients tend to display primary or acquired cytogenetic resistance, which hinders the overall success of IM therapy (Onmaz et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia

et al. 2020

View full text Add to dashboard Cite

Imatinib mesylate (IM) is the standard treatment for advanced, metastatic gastrointestinal stromal tumors (GISTs) and chronic myeloid leukemia (CML) with a fixed daily standard dosage via the oral route. Interindividual and intraindividual variability in plasma concentrations have been closely linked to the efficacy of IM therapy. Therefore, this review identifies and describes the key factors influencing the plasma concentration of IM in patients with GISTs and CML. We used the following keywords to search the PubMed, EMBASE, Ovid, Wangfang, and CNKI databases to identify published reports: IM, plasma concentration, GISTs, CML, drug combination/interaction, pathology, and genotype/genetic polymorphism, either alone or in combination. This literature review revealed that only 10 countries have reported the mean concentrations of IM in GISTs or CML patients and the clinical outcomes in different ethnic groups and populations. There were totally 24 different gene polymorphisms, which were examined for any potential influence on the steady-state plasma concentration of IM. As a result, some genotype locus made discrepant conclusion. Herein, the more sample capacity, multicenter, long-term study was worthy to carry out. Eleven reports were enumerated on clinical drug interactions with IM, while there is not sufficient information on the pharmacokinetic parameters altered by drug combinations with IM that could help in investigating the actual drug interactions. The drug interaction with IM should be paid more attention in the future research.

show abstract

Synthesis, characterization and in vitro anti-proliferative effects of pentacyclic triterpenoids

et al. 2021

View full text Add to dashboard Cite

Determination of serum imatinib and its' metabolite in patients chronic myeloid leukemia

Cited by 7 publications

References 26 publications

Therapeutic Drug Monitoring of Imatinib and N‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study

Therapeutic Drug Monitoring of Imatinib and N‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia

Synthesis, characterization and in vitro anti-proliferative effects of pentacyclic triterpenoids

Contact Info

Product

Resources

About